Topic:

M&A

Latest Headlines

Latest Headlines

Zimmer makes a divestiture proposal to appease EU regulators in Biomet acquisition

To address the European Commission's concerns about its proposed $13.4 billion acquisition of Biomet, Zimmer Holdings has proposed the divestiture of "one unicompartmental knee brand and one elbow brand" in the European Economic Areas as well as "one total knee brand" in two European countries.

Britain's BTG scoops up pulmonology outfit PneumRx for up to $475M

British healthcare group BTG is snatching up interventional pulmonology outfit PneumRx in a deal worth up to $475 million, getting its hands on the company's device for severe emphysema and diversifying its product offerings.

Analysts: Avanir could have scored higher bids--but now, its hands may be tied

Avanir, which agreed to sell itself to Otsuka earlier this week for $3.5 billion, may have been able to snag another price, some analysts figure. Problem is, it may too late to do anything about it.

Will buyers go after Mylan once it inverts? Don't count on it, analyst says

As Mylan gears up to close a $5.3 billion deal to buy a chunk of Abbott's generics business and shift its tax base to the Netherlands, some investors are speculating it could itself become a target for another stateside company looking for a tax inversion. But to that, Sanford Bernstein analyst Tim Anderson says they shouldn't hold their breath.

Medtronic sells $17B in bonds to fund Covidien buy

Medtronic has sold $17 billion in bonds to fund its $43 billion acquisition of Covidien that's still expected to close early next year. The medical device giant had been expecting to fund the deal mostly with ex-U.S. cash, but opted instead for debt in order to avoid potential issues with U.S. regulators seeking to crack down on tax inversion deals.

Roche dives into prenatal Dx space with Ariosa purchase

Roche has been on a diagnostics roll as of late, pushing for regulatory approval of proprietary technology and striking deals to gain a stronger foothold in emerging markets. Now, the Swiss drugmaker is entering the prenatal diagnostics space with its purchase of Ariosa Diagnostics.

Roche jumps into prenatal testing market with Ariosa Diagnostics buy

Roche is diving into the prenatal testing business, snatching up Ariosa Diagnostics to expand its diagnostics offerings and to get its hands on the company's noninvasive prenatal test for genetic abnormalities.

Otsuka spends $3.5B for Avanir--and patent-cliff protection

Otsuka's patent cliff is coming, with the expiration date on best-seller Abilify's IP shield just around the corner. But now, the Japanese pharma has signed a $3.5 billion agreement to pick up Avanir Pharmaceuticals that could help soften the blow.

Otsuka buys Avanir and its portfolio of repurposed generics for $3.5B

Avanir has made something of a reputation for itself by mixing a pair of generics--a cough suppressant and an old heart medicine--into a new elixir that can calm an emotional outburst. And Japan's Otsuka has stepped in to snap up the company, its product and a pipeline of repurposed meds for a hefty $3.5 billion.

FTC orders Novartis to sell nicotine patch biz to approve consumer deal with GSK

The U.S. Federal Trade Commission found only one antitrust wrinkle in the combo of the consumer health units of GlaxoSmithKline and Novartis and says it has been ironed out. Novartis will sell its Habitrol nicotine patch business so the new joint venture will not have too much market sway in pricing of nicotine patches in the U.S.